STING1 and breast carcinoma: PARPi activates the “stimulator of interferon genes” (STING) pathway in breast carcinoma, upregulating PD-L1; in BRCA wild-type PC cell lines, STING upregulation occurred after PARPi administration without increasing the PD-L1 expression [129].